{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:54:44Z","timestamp":1781528084066,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eprac.2025.11.017","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:33:00Z","timestamp":1766017980000},"page":"442-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"32","author":[{"given":"Yufeng","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Yi-Wen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remigius","family":"van Alebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmohsen H.","family":"Al-Zalabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice P.","family":"Zeegers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Wesselius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.eprac.2025.11.017_bib2","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.3390\/ijms25137476","article-title":"Associations between diabetes mellitus and selected cancers","volume":"25","author":"Pliszka","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.eprac.2025.11.017_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.017_bib4","article-title":"The association between pioglitazone consumption and incidence of bladder cancer in type II diabetic patients: a systematic review and meta-analysis of observational studies","volume":"12","author":"Ramezannezhad","year":"2023","journal-title":"J Nephropathology"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.017_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/dom.13049","article-title":"Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes","volume":"20","author":"Garry","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.017_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13300-016-0152-4","article-title":"Diabetes pharmacotherapies and bladder cancer: a medicare epidemiologic study","volume":"7","author":"Mackenzie","year":"2016","journal-title":"Diabetes Ther"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.017_bib7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.017_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72967-8","article-title":"Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials","volume":"10","author":"Sinha","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.eprac.2025.11.017_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102637","article-title":"Bladder cancer with pioglitazone: a case-control study","volume":"16","author":"Malhotra","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.eprac.2025.11.017_bib10","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2025.11.017_bib11","unstructured":"(CTTI) CTTI. Aggregate analysis of clinicalTrials.gov (AACT) database. Clinical Trials Transformation Initiative. https:\/\/aact.ctti-clinicaltrials.org\/. [Accessed 20 June 2025]."},{"issue":"4","key":"10.1016\/j.eprac.2025.11.017_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"9","key":"10.1016\/j.eprac.2025.11.017_bib13","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"10.1016\/j.eprac.2025.11.017_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.017_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2025.11.017_bib16","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.017_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.017_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.eprac.2025.11.017_bib19","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.017_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2025.11.017_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.eprac.2025.11.017_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"10157","key":"10.1016\/j.eprac.2025.11.017_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2025.11.017_bib24","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13116","article-title":"Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study","volume":"20","author":"Dagogo-Jack","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"13","key":"10.1016\/j.eprac.2025.11.017_bib25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.017_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-017-0593-8","article-title":"A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus","volume":"16","author":"Gantz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.017_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","article-title":"Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"59","author":"Nauck","year":"2016","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.017_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2025.11.017_bib29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.eprac.2025.11.017_bib30","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.11.017_bib31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dom.12543","article-title":"Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes","volume":"17","author":"Matthaei","year":"2015","journal-title":"Diabetes Obesity Metabolism"},{"issue":"3","key":"10.1016\/j.eprac.2025.11.017_bib32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.017_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obesity Metabolism"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.017_bib34","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.017_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet Med"},{"issue":"14","key":"10.1016\/j.eprac.2025.11.017_bib36","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.eprac.2025.11.017_bib37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.017_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)--a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.eprac.2025.11.017_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.11.017_bib40","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/j.1464-5491.2012.03624.x","article-title":"A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin","volume":"29","author":"Violante","year":"2012","journal-title":"Diabetic Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.017_bib41","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"issue":"9493","key":"10.1016\/j.eprac.2025.11.017_bib42","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2025.11.017_bib43","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","article-title":"Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis","volume":"47","author":"Xu","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.017_bib44","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.1038\/s41598-017-07921-2","article-title":"Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.eprac.2025.11.017_bib45","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.2337\/dc22-1174","article-title":"Sodium-glucose cotransporter 2 inhibitors and the short-term risk of bladder cancer: an international multisite cohort study","volume":"45","author":"Abrahami","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2025.11.017_bib46","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.2337\/dc21-1917","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of bladder and renal cancer: scandinavian cohort study","volume":"45","author":"Ueda","year":"2022","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2025.11.017_bib47","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2025.11.017_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.eprac.2025.11.017_bib49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.eprac.2025.11.017_bib50","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.euo.2024.04.006","article-title":"Association between GLP1R agonists and prostate, kidney, and bladder cancers","volume":"7","author":"Bukavina","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.eprac.2025.11.017_bib51","doi-asserted-by":"crossref","first-page":"12299","DOI":"10.1002\/cam4.5927","article-title":"Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study","volume":"12","author":"Chung","year":"2023","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.11.017_bib52","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2025.11.017_bib53","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume":"352","author":"Tuccori","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.017_bib54","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3346\/jkms.2014.29.2.238","article-title":"Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study","volume":"29","author":"Jin","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.eprac.2025.11.017_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","article-title":"The application of lag times in cancer pharmacoepidemiology: a narrative review","volume":"84","author":"Hicks","year":"2023","journal-title":"Ann Epidemiol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2501328X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2501328X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:13:47Z","timestamp":1781525627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2501328X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1530891X2501328X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.11.017","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}